Navigation Links
N-Viro Fuel Technology Receives Alternative Energy Status From the U.S. Environmental Protection Agency

TOLEDO, Ohio, Jan. 16 /PRNewswire/ -- N-Viro International Corporation, (OTC Bulletin Board: NVIC), an environmental and materials operating company that owns patented technologies to convert various types of waste into beneficial alternative fuel products, announces its renewable biofuel technology, N-Viro Fuel(TM), has satisfied guidelines set forth by the U.S. Environmental Protection Agency (EPA) to qualify as an alternative energy source that may be utilized in commercial power generation.

Attaining this status means that N-Viro Fuel technology is now eligible to qualify for certain economic incentives that are granted alternative energy technologies, and it is also a catalyst for attaining permits in each state in a more timely manner. The Company plans to accelerate its development efforts as this designation is an important factor for its potential energy partners.

In a proactive approach, the Company requested the EPA determine whether N-Viro Fuel qualifies within current regulations as an alternative fuel product, as opposed to a waste product that would be subject to incineration. The result of its request was the receipt of a written determination from the EPA that N-Viro Fuel qualifies as an alternative fuel.

The EPA sets forth various and stringent regulations for technologies such as N-Viro Fuel to qualify as alternative fuel. These regulations encompass three different regulatory divisions: water, air and solid waste. The N-Viro Fuel technology, utilizing an alkaline/heat process to produce a fuel product, satisfies all requirements of the EPA 40 CFR part 503 regulations and can be blended with coal for energy production or land applied for agricultural use as N-Viro Soil(TM). The Company's technologies can convert waste products that traditionally are landfilled, into safe, beneficial and renewable long-term energy solutions.

Timothy Kasmoch, CEO and President of N-Viro International said, "Receiving the designation from the U.S. EPA for N-Viro Fuel technology is a major milestone for our Company. This designation is an extremely important factor for state and federal regulators to issue permits, and it should help streamline the approval process."

He continued, "As a biomass-to-alternative energy technology, we believe that N-Viro Fuel will be an even more appealing solution to both the public and private sector. In the current environment, which encourages the use of renewable fuels, we are pleased to have a viable and tested biofuel to offer to the power generating industry as it faces increasing pressure to use alternative fuels."

Mr. Kasmoch concluded, "We have already announced two projects that are in development to manufacture N-Viro Fuel, one at Michigan State University and the other a joint venture to operate an N-Viro Fuel facility in the Mahoning Valley in Northeastern Ohio. We are optimistic the EPA designation will lend further credibility to our technology and we believe it will assist us in securing additional N-Viro Fuel projects in the near future."

About N-Viro Fuel(TM)

N-Viro Fuel is a relatively new and patented biomass alternative energy fuel that has physical and chemical characteristics similar to coal and is created from municipal biosolids and other organic wastes like manure and pulp and paper sludge. A major transformation is taking place in the coal industry and, more broadly, the global energy industry, as alternative, cleaner forms of energy take on increasing prominence. The one thing that remains constant despite the changes taking place is that coal will continue to be the cheapest and most abundant form of energy available in the U.S. for the near term. N-Viro Fuel is manufactured from a variety of organic wastes by blending the waste material with one or more mineral by-products and drying the mixture. The resulting product, N-Viro Fuel, is blended with coal or petroleum coke and burned as a partial coal substitute in coal-fired power plants. An important advantage of the waste biomass-derived fuel is the ammonia that is released from the wastes in the process. This ammonia is available to be used as a substitute for ammonia or urea for NOx removal.

About N-Viro International Corporation

N-Viro International Corporation is an alternative energy and environmental and materials operating company that develops, licenses and operates its technology to municipalities and private companies. N-Viro currently has two facilities in operation and two others in development. N-Viro's patented processes use lime and/or mineral-rich, combustion byproducts to treat, pasteurize, immobilize and convert wastewater sludge and other bio-organic wastes into biomineral agricultural and soil-enrichment products with real market value; or into alternative fuel for burning in electrical generating facilities and other processes employing the combustion of coal or other materials. More information about N-Viro International can be obtained by contacting the office or on the Internet at or by e-mail inquiry to

Special Cautionary Note Regarding Forward-Looking Statements

The Company cautions that words used in this document such as "expects," "anticipates," "believes" and "may," as well as similar words and expressions used herein, identify and refer to statements describing events that may or may not occur in the future. These forward-looking statements and the matters to which they refer are subject to considerable uncertainty that may cause actual results to be materially different from those described herein. For example, while the Company believes that trends in the alternative energy sector are moving in favor of the Company's technology, such trends may not continue or may never result in increased sales or profits to the Company because of the availability of competing processes and products. The lack of acceptance of the Company's technologies and the existence of alternative or competing technologies and products could adversely affect the Company's ability to achieve its strategic goals of entering into arrangements with customers, including power generation companies, relating to the production and supply of N-Viro Fuel. Further, the success and profitability of the N-Viro Fuel technology will depend on the actual revenues and expenses of the Company, which may differ from the Company's estimates. Factors that may cause expenses to differ from the Company's expectations include, fuel and transportation costs, labor costs and costs relating to the treatment and processing of the biosolids and creation of the N-Viro Fuel. All of these factors, and other factors, will affect the viability and profitability of the N-Viro Fuel technology and adversely affect the financial results of the Company. Additional information about these and other factors that may adversely affect these forward-looking statements are contained in the Company's reports, including its Annual Report on Form 10-KSB, as amended, and other filings with the Securities and Exchange Commission. The Company assumes no obligation to update forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws.

Contact: Porter, LeVay & Rose, Inc.

               (212) 564-4700

SOURCE N-Viro International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. N-Viro International Corporation Announces Dismissal of Lawsuit Against It
2. Biotechnology Value Fund, L.P. To Make Tender Offer For Any And All Outstanding Shares Of Avigen At $1.00 Per Share
3. BioSpace and the Massachusetts Biotechnology Council Inc. Launch 2009 Genetown™ Hotbed Campaign
4. Lafayette General Medical Center is the First Hospital in Louisiana to Use Genetic-Based Technology to Test for Respiratory Disease
5. Trinitas Comprehensive Cancer Center Now Offering Cancer Patients Faster, Ultra-Precise Radiation Using New RapidArc Technology
6. Biotechnology Veteran Michael Webb Joins Boston-based Investment Bank as Senior Advisor
7. Biotechnology Value Fund, L.P. Calls Special Meeting of Avigen Stockholders To Remove Incumbent Directors and Elect Slate of Stockholder-Focused Nominees
8. ABAXIS Announces Worldwide Animal Health Licensing Agreement for Rapid Test Technology
9. MicroDose and Nexus6 Announce Collaboration to Evaluate Application of Remote Patient Compliance Monitoring Technology with MicroDoses Electronic Dry Powder Inhaler
10. Sigma-Aldrich Acquires Seppro(R) Depletion Technology From GenWay Biotech
11. New one-of-a-kind technology will fly on 2 NASA missions
Post Your Comments:
(Date:10/9/2015)... , Oct. 9, 2015 Governor ... clinical stage biopharmaceutical company focused on developing T-cell receptor ... high-paying jobs with a new expansion project. ... news for the commonwealth as 110 new, high-paying jobs ... Tom Wolf . "My budget proposal includes sustained funding ...
(Date:10/9/2015)...  Pulmatrix, Inc., (NASDAQ: PULM ) will be webcasting ... th Annual BIO Investor Forum on Tuesday, ... --> th Annual BIO Investor Forum ... pm EDT). --> Pulmatrix will be presenting ... on Thursday, October 15, 2015 at 8:30 am EDT. Additionally, ...
(Date:10/8/2015)... BELLINGHAM, Washington, USA, and CARDIFF, UK (PRWEB) , ... October 08, ... ... noninvasive light-based imaging technology to literally see inside the living brain, providing a new ... over time. , The work is reported by Woo June Choi and Ruikang Wang ...
(Date:10/8/2015)...  Genetic testing for mutations beyond those currently recommended ... couples at risk of having a child with cystic ... 2015 American Society of Human Genetics (ASHG) Annual Meeting, ... Maryland . The study is one of four ... are presenting at the conference this week demonstrating the ...
Breaking Biology Technology:
... Commercialization and Supply Agreement, Company to Host Conference Call at 12:30 p.m. ... ... 2007, LEXINGTON, Mass., Sept. 19 Indevus,Pharmaceuticals, Inc. (Nasdaq: ... acquisition of Esprit Pharma, has obtained the,United States rights to SANCTURA(R) and ...
... Ventures, Kleiner Perkins ... Ventures, Strong Endorsement of Technology Pioneer at Forefront of Developing No- ... Compromise Biofuels, ... renewable hydrocarbon biofuels, today,announced that it closed the first tranche of its $70 ...
... - IDF Launches New Guideline for the ... the new global guideline for diabetes care which,includes ... people with diabetes should have their blood glucose ... diabetes control and reduce the,risk of complications, particularly ...
Cached Biology Technology:
(Date:9/24/2015)... September 24, 2015 ... 2015 Kerv ( ... lanserar idag världens första kontaktlösa betalningsring på ... 77 000 GBP för massproduktion via crowdfunding.  ... ) , Kerv-bärare kan göra ...
(Date:9/10/2015)... , Sept. 10, 2015 Pursuant Health ... Wellness to create an interactive, image-based health risk ... and wellness kiosk.  The unique assessment quantifies user ... number that suggests an individual,s biological age based ... as measured by the kiosk. Comprised ...
(Date:9/8/2015)... BOSTON , Sept. 8, 2015  Affectiva, ... of Emotion as a Service, a new data ... Based on Affectiva,s highly accurate and ... and analytics capabilities, slated to transform industries such ... app development, retail, customer experience, online education, HR, ...
Breaking Biology News(10 mins):
... For the first time, researchers have been able to confine ... role in photosynthesis, without having to pin it down so ... first practical application to proteins of a recently developed technique, ... the dynamic behavior of the molecule for more than one ...
... system science disciplines recently gathered to address a major ... future? Of course, possible answers to this question ... conditions were to alter local vegetation, how would this ... questions with certainty would allow us to manage better ...
... , SEATTLE, WA March 10, 2010 -- The ... genome sequences of a human family of four. The findings ... the University of Luxembourg was published online today by Science ... benefit of sequencing entire families, including lowering error rates, identifying ...
Cached Biology News:
Request Info...
Recombinant Equine TNF-alpha/TNFSF1A, CF...
Recombinant Equine IL-4, CF...
actin from rabbit muscle Cell Biology Cytoskeletal Probes Actin and Actin Probes...
Biology Products: